Literature DB >> 8405059

Viral hemagglutinin augments peptide-specific cytotoxic T cell responses.

C Ertel1, N S Millar, P T Emmerson, V Schirrmacher, P von Hoegen.   

Abstract

In attempt to increase the induction of peptide-specific cytolytic T cells (CTL) we investigated the effect of the Newcastle disease virus (NDV) hemagglutinin-neuraminidase (HN) gene product on the activation of peptide-specific CTL. Spleen cells of CH3 mice immunized against the influenza nucleoprotein peptide 50-63 (NP 50-63) were restimulated in vitro (i) with peptide-pulsed syngeneic fibroblast cells (Ltk-) as antigen-presenting cells, which were in addition (ii) infected with NDV or (iii) stably transfected with the HN cDNA of NDV. A greater than sixfold increase in peptide-specific CTL responses was observed in cultures restimulated with peptide-pulsed Ltk- cells which co-expressed viral hemagglutinin due to either infection or transfection. A similar augmentation was seen in CTL responses against other types of antigen (major histocompatibility complex alloantigens, minor histocompatibility antigens or tumor antigens) when suboptimal cultures were stimulated with the respective antigen-presenting cells modified by NDV infection. These findings suggest that NDV or viral HN expressed on antigen-presenting cells or tumor cells can exert a T cell co-stimulatory function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405059     DOI: 10.1002/eji.1830231032

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

Review 2.  Biotherapy of cancer. Perspectives of immunotherapy and gene therapy.

Authors:  V Schirrmacher
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

Review 3.  Safety and clinical usage of newcastle disease virus in cancer therapy.

Authors:  Han Yuen Lam; Swee Keong Yeap; Mehdi R Pirozyan; Abdul Rahman Omar; Khatijah Yusoff; Abd Aziz Suraini; Noorjahan Banu Alitheen
Journal:  J Biomed Biotechnol       Date:  2011-10-26

4.  Induction of apoptosis in MCF-7 cells by the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus Malaysian strain AF2240.

Authors:  Mohamed Ghrici; Mohamed El Zowalaty; Abdul Rahman Omar; Aini Ideris
Journal:  Oncol Rep       Date:  2013-06-27       Impact factor: 3.906

Review 5.  Immunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients.

Authors:  Volker Schirrmacher
Journal:  Int J Mol Sci       Date:  2017-05-20       Impact factor: 5.923

6.  Regulation of Constitutive Interferon-Stimulated Genes (Isgs) in Tumor Cells Contributes to Enhanced Antitumor Response of Newcastle Disease Virus-Infected Tumor Vaccines.

Authors:  Mai Takamura-Ishii; Takaaki Nakaya; Katsuro Hagiwara
Journal:  Cancers (Basel)       Date:  2018-06-06       Impact factor: 6.639

7.  Comparative Efficacy of Preoperative, Postoperative, and Perioperative Treatments for Resectable Colorectal Liver Metastases: A Network Meta-Analysis.

Authors:  Chao Huang; Jun Huang; Hongliang Luo; Zhen Zong; Zhengming Zhu
Journal:  Front Pharmacol       Date:  2019-09-18       Impact factor: 5.810

Review 8.  Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.

Authors:  Volker Schirrmacher; Stefaan van Gool; Wilfried Stuecker
Journal:  Biomedicines       Date:  2019-08-30

Review 9.  Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.

Authors:  Volker Schirrmacher; Philippe Fournier
Journal:  Methods Mol Biol       Date:  2009

10.  Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host.

Authors:  Philippe Fournier; Volker Schirrmacher
Journal:  Biology (Basel)       Date:  2013-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.